AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 4 - (NewsRx.com & NewsRx.net) -- Hyalozyme Therapeutics, Inc., has completed a $9.2 million financing led by Grove Capital.
The financing also included an option to purchase an additional $15.9 million in warrants callable by Hyalozyme. Ritchie Capital, Cimarron Biomedical Investors, and Colt Ventures participated in the round. Brean Murray & Co., Inc., acted as placement agent. Kirkpatrick & Lockhart, LLP, acted as counsel to Grove Capital.
"Hyalozyme has successfully developed a recombinant human enzyme product that will dramatically improve current treatment options in the therapeutic areas of infertility, ophthalmology, and oncology," said Peter G. Geddes of Grove Capital. "The company has two near-term product candidates as well as a number of significant opportunities in its growing pipeline. We are excited about helping Hyalozyme ...
Source: HighBeam Research, Enzyme company completes $9.2 million financing.